Clinigence Holdings (NUTX) AI Stock Analysis

• Market Cap: $500.24M
• Dividend Yield: N/A
• Average Volume (3M): 277.63K
• Price to Earnings (P/E): 7.5
• Beta (1Y): 2.29
• Revenue Growth: 141.25%
• EPS Growth: N/A
• Country: US
• Employees: 800
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -5.43
• Shares Outstanding: 5,555,116
• 10 Day Avg. Volume: 286,465
• 30 Day Avg. Volume: 277,634
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.06
• Enterprise Value/Revenue: 0.85
• Enterprise Value/Gross Profit: 1.73
• Enterprise Value/Ebitda: 2.47
• 1Y Price Target: $252.50
• Price Target Upside: 181.24% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 67 Neutral
• Price Target: $97.00 ▲(8.04% Upside)

Nutex Health's overall stock score reflects strong financial performance and attractive valuation, offset by technical weakness and legal risks. The company's significant revenue growth and profitability are promising, but increased leverage and legal challenges warrant caution.

Positive Factors

Expansion Plans

Nutex Health Inc. is on track to open 2–3 new micro-hospitals during 2025, indicating growth and expansion potential.

Revenue Growth

Nutex reported a 1Q beat with revenue of $211.9M, up 214% year over year.

Successful Arbitration

Successful rate arbitration with payors accounted for approximately $105M of revenue, significantly higher than the estimate.

Negative Factors

Accounting Issues

Nutex filed an NT 10-Q notification of inability to timely file its 10-Q due to the incorrect accounting classification of certain non-cash obligations, leading to the need for restatements.

Legal Challenges

Potential headwinds to NUTX's stock price include accounting restatements, arbitration dynamics, and lawsuits against Nutex's primary arbitration vendor, HaloMD.

Clinigence Holdings Business Overview & Revenue Model

Company Description

Nutex Health, Inc. operates as a technology-enabled healthcare services company. It operates through two divisions: Hospital division and Population Health Management division. The Hospital division implements and operates health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments. This division owns and operates 21 facilities in 8 states. The Population Health Management division owns and operates provider networks, such as independent physician associations. Its management services organizations provide management, administrative, and other support services to its affiliated hospitals and physician groups. This division's cloud-based proprietary technology platform aggregates data across multiple information systems, settings, and sources to create a holistic view of each patient and provider, as well as allows to deliver care. The company is based in Houston, Texas.

How the Company Makes Money

Clinigence Holdings generates revenue primarily through the sale of its software solutions and services to healthcare providers, payers, and other stakeholders in the healthcare ecosystem. The company operates a subscription-based model, where customers pay recurring fees for access to its analytics platforms and telehealth services. Additionally, Clinigence may earn revenue through consulting services that help healthcare organizations optimize their operations and implement best practices in population health management. Strategic partnerships with healthcare providers, technology firms, and payer organizations also contribute to its revenue, enabling Clinigence to expand its market reach and enhance its service offerings.

Clinigence Holdings Financial Statement Overview

Summary

Clinigence Holdings demonstrates solid financial performance with notable revenue growth and profitability improvements. While the company shows efficient operational cash flow management, the balance sheet highlights increased leverage, which could pose future risks. Overall, the company is on a promising trajectory but should focus on stabilizing margins and managing leverage.

Income Statement

Clinigence Holdings shows strong revenue growth with a significant increase in total revenue on a TTM basis compared to previous periods. The gross profit margin has improved, indicating efficient cost management. Net profit margin is healthy, reflecting profitability. However, historical volatility in EBIT and EBITDA margins suggests potential instability.

Balance Sheet

The balance sheet reflects moderate financial leverage with a debt-to-equity ratio that has increased, potentially raising risk. However, the return on equity is robust, signaling effective use of equity. Equity ratio is reasonable, indicating a stable asset base but with room for improvement in reducing liabilities.

Cash Flow

Operating cash flow has improved significantly, supporting a positive free cash flow trajectory. The operating cash flow to net income ratio suggests strong operational efficiency. However, historical fluctuations in free cash flow growth underscore potential variability in cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	624.28M	479.95M	247.65M	219.29M	331.53M	273.42M
Gross Profit	304.44M	196.26M	34.77M	13.45M	179.28M	271.60M
EBITDA	214.15M	148.65M	-14.58M	-393.96M	183.45M	-5.12M
Net Income	67.18M	52.18M	-45.79M	-424.78M	132.59M	105.97M
Balance Sheet
Total Assets	761.92M	655.32M	398.25M	431.75M	394.65M	308.55M
Cash, Cash Equivalents and Short-Term Investments	84.73M	43.58M	22.00M	34.26M	36.12M	25.51M
Total Debt	341.36M	340.30M	275.76M	267.20M	178.55M	150.12M
Total Liabilities	487.04M	453.43M	319.14M	311.42M	203.07M	161.19M
Stockholders Equity	197.11M	146.34M	61.45M	95.86M	114.65M	85.81M
Cash Flow
Free Cash Flow	69.43M	20.85M	-8.24M	35.97M	136.51M	25.48M
Operating Cash Flow	71.07M	23.15M	1.26M	50.61M	173.43M	86.67M
Investing Cash Flow	-2.00M	-2.67M	-11.24M	-4.34M	-36.98M	-61.19M
Financing Cash Flow	-11.41M	1.09M	-2.27M	-48.13M	-125.85M	-7.97M

Clinigence Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 89.78
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUTX, the sentiment is Negative. The current price of 89.78 is below the 20-day moving average (MA) of 92.74, below the 50-day MA of 104.42, and above the 200-day MA of 81.57, indicating a neutral trend. The MACD of -3.37 indicates Negative momentum. The RSI at 43.25 is Neutral, neither overbought nor oversold. The STOCH value of 23.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NUTX.

Clinigence Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HSTM	75 Outperform	$829.95M	42.09	5.81%	0.43%	3.50%	13.99%
NUTX	67 Neutral	$500.24M	7.54	51.65%	―	141.25%	―
TXG	56 Neutral	$1.75B	―	-11.30%	―	2.02%	65.33%
EVH	55 Neutral	$1.09B	―	-13.38%	―	-6.71%	-71.40%
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
HCAT	50 Neutral	$246.31M	―	-28.42%	―	5.55%	-0.99%
DH	49 Neutral	$557.10M	―	-64.27%	―	-5.24%	23.59%

Clinigence Holdings Corporate Events

Nutex Health Faces Securities Class Action Lawsuit

On August 22, 2025, a securities class action complaint was filed against Nutex Health Inc. in the United States District Court for the Southern District of Texas. The complaint, which follows a recent short seller report, names the company’s top executives as defendants and alleges violations of the Securities Exchange Act of 1934. Nutex Health disputes the allegations and plans to defend itself vigorously, though an adverse ruling could significantly impact its financial position or operations.

Clinigence Holdings Faces Nasdaq Delisting Notice

On August 20, 2025, Nutex Health Inc. received a notice from Nasdaq due to a delayed filing of its Quarterly Report, risking delisting if not resolved by October 20, 2025. The company is actively working to complete its financial filings. Additionally, Nutex Health disclosed that its previously issued financial statements should not be relied upon due to non-cash classification changes, which are being corrected. Despite these challenges, Nutex Health reported significant financial growth for the three and six months ended June 30, 2025, with total revenue increasing by over 200% compared to the previous year, driven by mature hospitals’ performance.

Clinigence Holdings Stockholders Approve Key Decisions

At the annual meeting of stockholders of Nutex Health Inc. held on July 14, 2025, several key decisions were made. All seven director nominees were elected for a one-year term, the compensation of executive officers was approved, an amendment to the 2023 Equity Incentive Plan was passed, and Grant Thornton LLP was ratified as the independent accounting firm for 2025.

Nutex Health COO Joshua DeTillio Resigns

On July 8, 2025, Joshua DeTillio, the Chief Operating Officer of Nutex Health, Inc., announced his resignation effective August 8, 2025, to take on a CEO role at another company. His departure is amicable, with no disputes or disagreements involved, and the company’s Board of Directors is actively searching for his replacement.